{"gene":"CDC73","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2005,"finding":"Parafibromin (CDC73) is a component of the human PAF1 complex, physically associating with PAF1, LEO1, and CTR9 homologs, and co-purifies with non-phosphorylated, Ser2-phosphorylated, and Ser5-phosphorylated forms of the RNA polymerase II large subunit. Cotransfection data suggest parafibromin can interact with a histone methyltransferase complex that methylates histone H3 on lysine 4.","method":"Cellular purification of parafibromin followed by mass spectrometry identification of associated proteins; co-immunoprecipitation; immunofluorescence; cotransfection assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP and mass spectrometry, replicated in two independent papers (PMID 15632063, 15923622)","pmids":["15632063"],"is_preprint":false},{"year":2005,"finding":"Parafibromin physically interacts with human orthologs of yeast Paf1 complex components (PAF1, LEO1, CTR9) involved in transcription elongation and 3' end processing, and associates with RNA polymerase II large subunit phosphorylated on Ser5 or Ser2 of its CTD. These interactions depend on a C-terminal domain of parafibromin deleted in ~80% of clinically relevant mutations. RNAi-induced downregulation of parafibromin promotes entry into S phase.","method":"Co-immunoprecipitation; RNAi knockdown with cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with multiple subunits, functional RNAi phenotype, replicated across labs","pmids":["15923622"],"is_preprint":false},{"year":2006,"finding":"Drosophila Hyrax (parafibromin ortholog) and human Parafibromin are required for nuclear transduction of the Wnt/Wg signal and bind directly to the C-terminal region of beta-catenin/Armadillo. The transactivation potential of Parafibromin/Hyrax depends on recruitment of Pygopus to beta-catenin/Armadillo, identifying the PAF1 complex as a direct nuclear effector of Wnt signaling.","method":"Genetic epistasis in Drosophila; direct binding assays; co-immunoprecipitation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — genetic epistasis in Drosophila combined with direct binding assays; validated in mammalian cells; highly cited","pmids":["16630820"],"is_preprint":false},{"year":2005,"finding":"Transient overexpression of wild-type parafibromin, but not its Leu64Pro missense mutant, inhibits cell proliferation and blocks expression of cyclin D1, a key cell cycle regulator, demonstrating a functional role for parafibromin in repressing cyclin D1.","method":"Transient overexpression; cell proliferation assay; Western blot for cyclin D1","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — overexpression with mutant control and defined molecular readout, single lab","pmids":["15580289"],"is_preprint":false},{"year":2006,"finding":"Parafibromin contains a functional monopartite nuclear localization signal (NLS) at residues 136-139 (KKXR) that is evolutionarily conserved and critical for nuclear localization; deletion or mutation of this NLS abolishes nuclear targeting.","method":"Site-directed mutagenesis; confocal fluorescence microscopy of GFP-tagged constructs; Western blot of nuclear/cytoplasmic fractions","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis with direct imaging and fractionation, confirmed by two independent studies (PMID 16964291, 16116486)","pmids":["16964291"],"is_preprint":false},{"year":2005,"finding":"A functional bipartite nuclear localization signal (NLS) in parafibromin was identified at residues 125-139 (KRAADEVLAEAKKPR); the C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. Specific HRPT2 mutations that truncate parafibromin upstream of or within this NLS disrupt nuclear localization.","method":"Expression of GFP-tagged wild-type and mutant parafibromin; confocal fluorescence microscopy","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — mutagenesis with direct imaging, replicated by PMID 16964291","pmids":["16116486"],"is_preprint":false},{"year":2009,"finding":"CDC73 (Cdc73/parafibromin) physically associates with the cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CstF) complexes required for mRNA 3' end maturation. Immunodepletion of the Cdc73-CPSF-CstF complex abolishes 3' mRNA processing in vitro. CDC73 siRNA leads to decreased INTS6 mRNA abundance and decreased CPSF/CstF association with the INTS6 locus.","method":"Co-immunoprecipitation; in vitro mRNA 3' processing assay with immunodepletion; siRNA knockdown; microarray; chromatin immunoprecipitation (ChIP)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution/immunodepletion with multiple orthogonal methods","pmids":["19136632"],"is_preprint":false},{"year":2008,"finding":"Parafibromin inhibits cell proliferation and represses the c-myc proto-oncogene through both c-myc protein stabilization inhibition and promoter repression via the PAF1 complex. Chromatin immunoprecipitation demonstrates direct occupancy of the c-myc promoter by parafibromin and other PAF1 complex subunits. Knockdown of c-myc blocks the proliferative effect of parafibromin/Paf1 RNAi.","method":"RNAi knockdown; cell proliferation assay; ChIP; Western blot; reporter assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating direct promoter occupancy plus epistasis through c-myc knockdown rescue, multiple orthogonal methods","pmids":["18987311"],"is_preprint":false},{"year":2009,"finding":"Parafibromin interacts with the histone methyltransferase SUV39H1 via its central region (residues 128-227), recruits SUV39H1 to the promoter and coding regions of cyclin D1, and induces H3 K9 methylation (but not H3 K4 methylation) at the cyclin D1 locus, thereby repressing cyclin D1 expression.","method":"Co-immunoprecipitation; ChIP; RNAi knockdown; reporter assay; deletion mapping","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — ChIP with direct mechanistic readout, co-IP with domain mapping, RNAi epistasis","pmids":["19906718"],"is_preprint":false},{"year":2011,"finding":"CDC73 interacts with the E3 ubiquitin ligase ring finger proteins RNF20 and RNF40 (which form a heterodimer catalyzing monoubiquitination of histone H2B at K120). CDC73 binds to discrete but closely located residues on RNF20 and RNF40. Loss of nuclear CDC73 in vitro (by siRNA) or in CDC73-mutant parathyroid tumors significantly reduces H2B-K120 monoubiquitination, while H3-K4me3 remains unchanged.","method":"Yeast two-hybrid screen; co-immunoprecipitation; siRNA knockdown; immunohistochemistry of tumor tissue; Western blot for histone modifications","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — yeast two-hybrid plus Co-IP plus in vitro knockdown plus in vivo tumor analysis, multiple orthogonal methods","pmids":["22021426"],"is_preprint":false},{"year":2011,"finding":"SHP2 phosphatase dephosphorylates parafibromin on tyrosine residues. Tyrosine dephosphorylation by SHP2 enables parafibromin to stably bind beta-catenin, thereby activating Wnt target genes including cyclin D1 and c-myc, overriding the parafibromin/SUV39H1-mediated transrepression. Thus, SHP2 governs the opposing tumor suppressor vs. oncogenic functions of parafibromin.","method":"In vitro phosphatase assay; co-immunoprecipitation; reporter assay; Western blot; cell-based functional assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro phosphatase assay plus Co-IP plus functional reporter assays with mechanistic dissection","pmids":["21726809"],"is_preprint":false},{"year":2007,"finding":"Nuclear localization of parafibromin is required for its proapoptotic activity. Mutation of both a dominant bipartite NLS and a secondary NLS in the NH2-terminal region nearly abolishes nuclear targeting, significantly impairs association with endogenous Paf1 and Leo1, and abolishes the ability of overexpressed parafibromin to induce apoptosis. Endogenous parafibromin knockdown by RNAi inhibits basal apoptosis and camptothecin-induced apoptosis.","method":"Site-directed mutagenesis; co-immunoprecipitation; confocal fluorescence microscopy; RNAi; apoptosis assays","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 2 — mutagenesis linking NLS to Paf1 binding and functional apoptosis phenotype, multiple orthogonal methods","pmids":["17314275"],"is_preprint":false},{"year":2008,"finding":"Parafibromin interacts with muscle alpha-actinins (actinin-2 and actinin-3) but not non-muscle alpha-actinins, through its N-terminal region. Parafibromin can bundle/cross-link actin filaments in actin sedimentation assays. In differentiated myotubes, parafibromin co-localizes with actinins in the cytoplasm, whereas in proliferating myoblasts it is predominantly nuclear.","method":"Yeast two-hybrid; GST pull-down; co-immunoprecipitation; actin sedimentation assay; confocal microscopy","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal Co-IP and GST pull-down plus functional actin assay, single lab","pmids":["18687124"],"is_preprint":false},{"year":2008,"finding":"Parafibromin, as a transcription factor associated with the PAF complex, directly regulates genes involved in cell growth and survival (H19, Igf1, Igf2, Igfbp4, Hmga1, Hmga2, Hmgcs2) as shown by ChIP. Conditional homozygous deletion of Hrpt2 in mice causes embryonic lethality by E6.5, apoptosis in embryonic fibroblasts, and cachexia/death in adults.","method":"Conditional knockout mouse; cDNA microarray; chromatin immunoprecipitation; semi-quantitative RT-PCR; MEF culture with Cre-mediated deletion","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO mouse with ChIP and defined molecular readouts, multiple orthogonal methods","pmids":["18212049"],"is_preprint":false},{"year":2010,"finding":"Parafibromin regulates 3' processing of replication-dependent histone mRNA. Downregulation of parafibromin by siRNA or in vivo CDC73 mutations leads to uncleaved histone mRNA with polyadenylated tails, demonstrating a posttranscriptional role in histone mRNA 3' end processing.","method":"siRNA knockdown; RNA analysis (RT-PCR, Northern); analysis of tumor samples with in vivo mutations","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro knockdown plus in vivo mutation-correlated phenotype, single lab","pmids":["19908240"],"is_preprint":false},{"year":2016,"finding":"Dephosphorylated parafibromin competitively interacts with beta-catenin and Gli1, potentiating transactivation of Wnt- and Hedgehog-target genes in a mutually exclusive manner. Parafibromin also binds to the Notch intracellular domain (NICD), enabling concerted Wnt- and Notch-target gene activation. Tyrosine dephosphorylation by SHP2 potentiates and phosphorylation by PTK6 kinase attenuates these functions. Acute parafibromin loss in mouse intestine disorganizes epithelial architecture.","method":"Co-immunoprecipitation; reporter assays; conditional mouse knockout; immunofluorescence; cell-based assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple Co-IPs with competitive binding, reporter assays, in vivo mouse loss-of-function with defined epithelial phenotype","pmids":["27650679"],"is_preprint":false},{"year":2009,"finding":"Parafibromin/Hyrax acts as a positive component of Hedgehog signaling by directly binding Region 1 (the Su(fu) interaction domain) in the N-terminus of all three Gli proteins and Ci. Parafibromin forms a complex with Gli1, Gli2, and Gli3. RNAi knockdown of Parafibromin in mammalian cells diminishes transcriptional activity of Gli1 and Gli2.","method":"Drosophila genetic epistasis; RNAi in cell culture; co-immunoprecipitation; reporter assay","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis plus Co-IP plus RNAi functional assay, single lab","pmids":["19368795"],"is_preprint":false},{"year":2014,"finding":"Cytoplasmic parafibromin/hCdc73 physically associates with mature p53 mRNA in the cytoplasm and facilitates its degradation, thereby controlling p53-mediated apoptosis. Cytoplasmic hCdc73 interacts with eEF1Bγ and hSki8; this interaction is required to bind and destabilize p53 mRNA. A cancer-associated K34Q mutant shows enhanced p53 mRNA binding and reduces p53 expression.","method":"RNA immunoprecipitation (RIP); co-immunoprecipitation; mRNA stability assay; mutagenesis; cell viability assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — RIP identifying mRNA substrate, Co-IP of protein complex, mechanistic mutagenesis with functional readout","pmids":["25388829"],"is_preprint":false},{"year":2018,"finding":"YAP and TAZ transcriptional co-activator functions are inversely regulated by parafibromin's tyrosine phosphorylation state. Tyrosine-dephosphorylated parafibromin stimulates TAZ and beta-catenin cooperatively; tyrosine-phosphorylated parafibromin selectively activates YAP without interacting with beta-catenin.","method":"Co-immunoprecipitation; reporter assay; mutagenesis; cell-based functional assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP with phosphorylation-state dependency and reporter functional assays, single lab","pmids":["30227954"],"is_preprint":false},{"year":2015,"finding":"CDC73 interacts with components of the SCF/Cullin and INO80/NuA4 chromatin-remodeling complexes to promote histone ubiquitination, and is required for local chromatin decondensation at sites of DNA damage to promote homologous recombination repair. This function is related to but independent of CDC73's role in transcriptional elongation.","method":"Genome-wide siRNA screen; co-immunoprecipitation; RAD51 foci assay; HR repair assay; RPA foci assay","journal":"Cell discovery","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide screen with Co-IP and functional HR assay, single lab","pmids":["27462432"],"is_preprint":false},{"year":2019,"finding":"CDC73 interacts with RNA polymerase II in a phospho-CTD (carboxy-terminal domain)-dependent manner and is required for high ATR signaling, R-loop formation, and activation of the G2 checkpoint after PNUTS-PP1 depletion. ATR, RNAPII, and CDC73 co-immunoprecipitate.","method":"Co-immunoprecipitation; siRNA knockdown; ATR signaling assays; R-loop detection; checkpoint assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP with functional checkpoint and R-loop phenotype, single lab","pmids":["30541148"],"is_preprint":false},{"year":2022,"finding":"UBR5 (HECT-domain E3 ubiquitin ligase) polyubiquitinates CDC73 at Lys243, Lys247, and Lys257, leading to its proteasomal degradation. This ubiquitination depends on the non-phosphorylation state of CDC73 at Ser465. CDC73 acts as a molecular switch to modulate UBR5's pro-tumor activities in triple-negative breast cancer.","method":"Co-immunoprecipitation; ubiquitination assay; site-directed mutagenesis; Western blot; in vivo xenograft","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — direct ubiquitination assay with site-specific mutagenesis and functional in vivo data, single lab","pmids":["35551175"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of the N-terminal domain of human CDC73 (residues 1-111, hCDC73-NTD) at 1.02 Å resolution reveals a novel protein fold with an extended hydrophobic groove. Most pathogenic HPT-JT-associated missense mutations disrupt folding of the hydrophobic core of hCDC73-NTD, while others (e.g., K34Q) reduce thermostability.","method":"X-ray crystallography; limited proteolysis; biochemical thermostability assays","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 — crystal structure at atomic resolution with biochemical validation and mutant analysis","pmids":["29142233"],"is_preprint":false},{"year":2015,"finding":"LEOPARD syndrome-associated SHP2 mutants (Y279C, T468M, Q506P, Q510E) exhibit substantially reduced phosphatase activity toward tyrosine-phosphorylated parafibromin in an in vitro phosphatase assay, demonstrating parafibromin as a bona fide SHP2 substrate.","method":"In vitro phosphatase assay using tyrosine-phosphorylated parafibromin substrate; SHP2 mutant panel","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro enzymatic assay with multiple mutants, confirms parafibromin as SHP2 substrate","pmids":["26742426"],"is_preprint":false},{"year":2023,"finding":"In yeast, Cdc73 directly interacts with the transcription elongation factor Spt6 (through Spt6's tandem SH2 domain) and with the largest subunit of RNA polymerase II. These interactions can be detected in vitro. Rapid depletion of Spt6 dissociates Paf1 from chromatin and alters Paf1C-dependent histone modifications genome-wide. A central 105 amino acid region of Cdc73 is necessary and sufficient for binding Ctr9 and nuclear localization, and suppresses genome instability.","method":"Site-specific protein cross-linking in yeast cells; in vitro binding assay; auxin-inducible degron (rapid depletion); ChIP-seq; deletion analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo cross-linking identifying direct contacts, confirmed in vitro, combined with genome-wide ChIP and rapid depletion","pmids":["36928138"],"is_preprint":false},{"year":2010,"finding":"Parafibromin regulates the mRNA stability of CPEB1 (cytoplasmic polyadenylation element binding protein). Parafibromin occupies the CPEB1 locus as shown by ChIP. A genetic interaction between hyx/parafibromin and orb/CPEB was identified through Drosophila double heterozygote screens.","method":"Drosophila genetic screen; siRNA knockdown in mammalian cells; Western blot; chromatin immunoprecipitation","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — genetic interaction confirmed by ChIP and mammalian knockdown, single lab","pmids":["20339377"],"is_preprint":false},{"year":2010,"finding":"A central 105 amino acid region of Cdc73 in yeast is necessary and sufficient for suppressing gross chromosomal rearrangements, binding to the Paf1 complex via Ctr9, and nuclear localization. Loss of Cdc73 causes increased telomere dysfunction and accumulation of chromosomal rearrangements, mediated by partial telomere dysfunction.","method":"GCR assay; deletion analysis; co-immunoprecipitation; telomere length analysis; telomeric silencing assay; whole genome sequencing","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 — yeast deletion analysis with functional GCR assay and telomere assays, single lab","pmids":["29320491"],"is_preprint":false},{"year":2010,"finding":"Parafibromin deficiency (via L95P missense mutation) causes defective nucleolar localization and dominant-negative interference with endogenous parafibromin. The L95P mutant retains the ability to assemble with endogenous PAF1 complex components but is expressed at lower levels, is not rescued by proteasome inhibition, and enhances cell cycle progression and survival when transfected.","method":"Transfection; co-immunoprecipitation; confocal microscopy; cell cycle analysis; proteasome inhibitor treatment; flow cytometry","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 — functional mutagenesis with mechanistic imaging and Co-IP, single lab","pmids":["20304979"],"is_preprint":false},{"year":2012,"finding":"MicroRNA-155 (miR-155) directly targets the 3'-UTR of CDC73 mRNA, negatively regulating CDC73 expression. Ectopic miR-155 expression dramatically reduces CDC73 levels and enhances cell viability/reduces apoptosis; delivery of antagomir-155 increases CDC73 levels, decreases cell viability, and causes xenograft regression.","method":"miRNA overexpression/antagomir delivery; 3'-UTR reporter assay; Western blot; in vivo xenograft","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — functional miRNA-target interaction confirmed by rescue and in vivo data, single lab","pmids":["23166327"],"is_preprint":false}],"current_model":"CDC73/Parafibromin is a nuclear (and in some contexts cytoplasmic) component of the RNA polymerase II-associated PAF1 complex that regulates transcription elongation, histone modifications (H3K4 methylation, H2B-K120 monoubiquitination via RNF20/RNF40, and H3K9 methylation via SUV39H1), and mRNA 3' end processing (via CPSF/CstF); it directly represses oncogenes cyclin D1 and c-myc, is a direct transcriptional effector of Wnt, Hedgehog, and Notch signaling through physical binding to beta-catenin, Gli proteins, and NICD respectively, and its tumor suppressor vs. oncogenic activities are switched by SHP2/PTK6-regulated tyrosine phosphorylation/dephosphorylation; its stability is regulated by UBR5-mediated polyubiquitination, and its loss causes genome instability through defective telomere maintenance and impaired homologous recombination repair."},"narrative":{"teleology":[{"year":2005,"claim":"Identifying CDC73 as a bona fide PAF1 complex subunit resolved how a tumor suppressor gene product interfaces with the RNA Pol II transcription elongation machinery.","evidence":"Mass spectrometry of purified parafibromin complexes and reciprocal co-immunoprecipitation with PAF1, LEO1, CTR9, and phospho-Pol II CTD forms in human cells, replicated across two independent labs","pmids":["15632063","15923622"],"confidence":"High","gaps":["Stoichiometry of human PAF1 complex not determined","Which CDC73 surfaces directly contact each subunit was unknown"]},{"year":2005,"claim":"Demonstrating that overexpressed wild-type but not mutant parafibromin represses cyclin D1 and inhibits proliferation established CDC73's tumor-suppressive mechanism at a defined target gene.","evidence":"Transient overexpression with L64P mutant control, cyclin D1 Western blot, and cell proliferation assay","pmids":["15580289"],"confidence":"Medium","gaps":["Overexpression system; endogenous loss-of-function validation of cyclin D1 regulation was lacking","Mechanism of promoter-level repression not yet dissected"]},{"year":2005,"claim":"Mapping a nuclear localization signal in parafibromin explained why clinically observed truncating mutations cause loss of function by mislocalizing the protein.","evidence":"GFP-tagged mutagenesis with confocal microscopy and nuclear/cytoplasmic fractionation, confirmed independently","pmids":["16116486","16964291"],"confidence":"High","gaps":["Whether cytoplasmic parafibromin retains any function was unclear"]},{"year":2006,"claim":"Showing that parafibromin directly binds β-catenin and is required for Wnt nuclear transduction repositioned CDC73 from a general transcription factor to a signal-specific transcriptional effector.","evidence":"Drosophila genetic epistasis with Hyrax, direct binding assays, and co-immunoprecipitation with β-catenin in mammalian cells","pmids":["16630820"],"confidence":"High","gaps":["Whether binding is constitutive or signal-regulated was not known","Structural basis of β-catenin–parafibromin interface unresolved"]},{"year":2007,"claim":"Linking nuclear localization to both PAF1 complex assembly and proapoptotic activity demonstrated that CDC73's tumor suppression requires its nuclear role rather than cytoplasmic functions.","evidence":"NLS mutagenesis with co-immunoprecipitation for PAF1/LEO1 and apoptosis assays upon RNAi knockdown","pmids":["17314275"],"confidence":"High","gaps":["Downstream apoptotic pathway not fully delineated","Whether a cytoplasmic pool has independent pro-survival functions was unresolved"]},{"year":2008,"claim":"ChIP-based identification of c-myc as a direct PAF1-complex-occupied target gene, combined with epistatic rescue by c-myc knockdown, provided the first complete transcriptional circuit linking CDC73 loss to oncogene derepression and proliferation.","evidence":"ChIP for PAF1 complex subunits at the c-myc promoter; RNAi epistasis showing c-myc knockdown blocks parafibromin-depletion-induced proliferation","pmids":["18987311"],"confidence":"High","gaps":["Mechanism distinguishing repression at c-myc from activation at Wnt targets not clarified"]},{"year":2008,"claim":"Conditional knockout in mice proved CDC73 is essential for embryonic viability and identified downstream growth/survival gene targets (Igf axis, Hmga genes) by ChIP, moving from cell-line studies to organismal requirement.","evidence":"Conditional Hrpt2 knockout mouse with embryonic lethality at E6.5; cDNA microarray and ChIP in MEFs","pmids":["18212049"],"confidence":"High","gaps":["Tissue-specific requirements beyond early embryogenesis incompletely mapped","Relative contribution of individual target genes to lethality unknown"]},{"year":2009,"claim":"Discovery that CDC73 physically associates with CPSF/CstF and is required for mRNA 3′ end processing in vitro expanded its function beyond transcription elongation to co-transcriptional RNA maturation.","evidence":"Co-immunoprecipitation, immunodepletion abolishing in vitro 3′ processing, siRNA with ChIP showing loss of CPSF/CstF at a target locus","pmids":["19136632"],"confidence":"High","gaps":["Whether CDC73 directly contacts CPSF/CstF or acts via PAF1 complex bridging was not resolved","Genome-wide scope of 3′ processing dependency unknown"]},{"year":2009,"claim":"Identification of SUV39H1 as a CDC73-recruited histone methyltransferase that deposits H3K9me at the cyclin D1 locus provided a direct epigenetic mechanism for CDC73-mediated gene repression distinct from H3K4 methylation.","evidence":"Co-immunoprecipitation with domain mapping; ChIP showing H3K9 methylation at cyclin D1 promoter/coding regions dependent on parafibromin","pmids":["19906718"],"confidence":"High","gaps":["Whether SUV39H1 recruitment is gene-specific or genome-wide was unknown","H3K9me reader proteins downstream were not identified"]},{"year":2009,"claim":"Binding of parafibromin to all three Gli proteins and Drosophila Ci placed CDC73 as a shared nuclear effector of both Wnt and Hedgehog signaling pathways.","evidence":"Drosophila genetic epistasis; co-immunoprecipitation with Gli1/2/3; RNAi reducing Gli transcriptional activity","pmids":["19368795"],"confidence":"Medium","gaps":["Whether Wnt and Hedgehog inputs compete for CDC73 binding was unresolved","In vivo mammalian Hedgehog phenotype of CDC73 loss not tested"]},{"year":2010,"claim":"Mapping a minimal 105-aa Cdc73 region sufficient for Ctr9 binding, nuclear localization, and suppression of gross chromosomal rearrangements linked PAF1 complex integrity to genome stability through telomere maintenance.","evidence":"Yeast GCR assay, deletion analysis, co-immunoprecipitation with Ctr9, telomere length and silencing assays","pmids":["29320491"],"confidence":"Medium","gaps":["Mechanistic link between telomere dysfunction and GCR was correlative","Whether mammalian CDC73 loss also causes telomere defects was not tested"]},{"year":2011,"claim":"Demonstrating that SHP2-mediated tyrosine dephosphorylation of parafibromin switches it from a transcriptional repressor to a β-catenin-dependent transactivator provided the key regulatory logic explaining CDC73's dual tumor suppressor/oncogene behavior.","evidence":"In vitro SHP2 phosphatase assay; co-immunoprecipitation showing phosphorylation-dependent β-catenin binding; reporter assays","pmids":["21726809"],"confidence":"High","gaps":["Tyrosine residue(s) phosphorylated on CDC73 not identified","Kinase responsible for CDC73 tyrosine phosphorylation was unknown at this point"]},{"year":2011,"claim":"Showing that CDC73 interacts with the RNF20/RNF40 E3 ligase and is required for H2B-K120 monoubiquitination in cells and tumors established a second chromatin modification axis controlled by CDC73, distinct from H3K9 methylation.","evidence":"Yeast two-hybrid, co-immunoprecipitation, siRNA, immunohistochemistry of CDC73-mutant parathyroid tumors","pmids":["22021426"],"confidence":"High","gaps":["Whether CDC73 stimulates RNF20/RNF40 enzymatic activity or merely recruits it was unclear","Genome-wide pattern of H2Bub1 loss upon CDC73 mutation not mapped"]},{"year":2014,"claim":"Discovery that cytoplasmic parafibromin binds mature p53 mRNA via an eEF1Bγ/hSki8 complex and promotes its degradation revealed a post-transcriptional, non-PAF1-complex function that explains how cytoplasmic CDC73 can be oncogenic.","evidence":"RNA immunoprecipitation identifying p53 mRNA; co-immunoprecipitation with eEF1Bγ and hSki8; mRNA stability assays; K34Q cancer mutant with enhanced p53 mRNA binding","pmids":["25388829"],"confidence":"High","gaps":["Whether other mRNAs are similarly regulated by cytoplasmic CDC73 was not addressed","Structural basis of CDC73–mRNA interaction unknown"]},{"year":2015,"claim":"A genome-wide screen placing CDC73 in homologous recombination repair through chromatin decondensation at damage sites broadened CDC73's roles beyond transcription to DNA damage response.","evidence":"Genome-wide siRNA screen; RAD51/RPA foci assays; HR reporter assay; co-immunoprecipitation with SCF/Cullin and INO80/NuA4 components","pmids":["27462432"],"confidence":"Medium","gaps":["Whether the HR function depends on PAF1 complex or is CDC73-autonomous was not resolved","Direct DNA-damage-site recruitment mechanism unclear"]},{"year":2015,"claim":"Confirming parafibromin as a direct SHP2 substrate using LEOPARD syndrome mutants with reduced phosphatase activity validated the phosphorylation switch model with disease-relevant mutations.","evidence":"In vitro phosphatase assay with panel of LEOPARD-associated SHP2 mutants and tyrosine-phosphorylated parafibromin substrate","pmids":["26742426"],"confidence":"High","gaps":["In vivo relevance in LEOPARD syndrome patients not tested","Which tyrosine residues on CDC73 are dephosphorylated still unidentified"]},{"year":2016,"claim":"Showing that dephosphorylated parafibromin competitively binds β-catenin, Gli1, and NICD in a mutually exclusive manner, with PTK6 as the opposing kinase to SHP2, unified Wnt, Hedgehog, and Notch nuclear effector functions under a single phospho-switch.","evidence":"Co-immunoprecipitation with competitive binding; reporter assays; conditional mouse intestinal knockout with epithelial disorganization","pmids":["27650679"],"confidence":"High","gaps":["Structural basis for mutually exclusive binding not determined","In vivo consequences for Hedgehog and Notch targets in the intestine not individually dissected"]},{"year":2017,"claim":"The 1.02 Å crystal structure of the CDC73 N-terminal domain revealed a novel fold and explained how HPT-JT-associated missense mutations destabilize the protein, providing the first structural framework for interpreting clinical mutations.","evidence":"X-ray crystallography at atomic resolution; limited proteolysis; thermostability assays of pathogenic mutants","pmids":["29142233"],"confidence":"High","gaps":["Structure of the C-terminal PAF1-complex-interacting domain not solved","No co-crystal with any binding partner"]},{"year":2022,"claim":"Identification of UBR5-mediated polyubiquitination at specific lysines (K243/K247/K257) as a Ser465-phosphorylation-dependent degradation mechanism established how CDC73 protein levels are post-translationally controlled.","evidence":"Ubiquitination assays with site-directed mutagenesis; co-immunoprecipitation; in vivo xenograft in triple-negative breast cancer","pmids":["35551175"],"confidence":"Medium","gaps":["Kinase responsible for Ser465 phosphorylation not identified","Whether UBR5-mediated degradation is context-dependent across tissues not established"]},{"year":2023,"claim":"Direct cross-linking of Cdc73 to the Spt6 tSH2 domain and to Rpb1 in vivo, combined with rapid Spt6 depletion causing genome-wide loss of Paf1C from chromatin, established Spt6 as a critical bridge anchoring the PAF1 complex to elongating Pol II.","evidence":"Site-specific protein cross-linking in yeast; in vitro binding assay; auxin-inducible degron depletion with ChIP-seq","pmids":["36928138"],"confidence":"High","gaps":["Whether the Spt6–Cdc73 interaction is conserved in metazoans not tested","No structure of the Spt6–Cdc73–Pol II ternary complex"]},{"year":null,"claim":"Key unresolved questions include the identity of specific tyrosine residues phosphorylated on CDC73 that govern the repressor/activator switch, the structural basis for competitive β-catenin/Gli/NICD binding, and the full-length structure of CDC73 in complex with PAF1 complex subunits.","evidence":"","pmids":[],"confidence":"Low","gaps":["Phosphorylated tyrosine residues not mapped","No full-length CDC73 structure or PAF1 complex co-structure","Genome-wide target specificity of repression vs. activation functions not delineated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,7,8,10,15,16]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[17]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,6,9]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[8,9]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,4,5,11,24]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[12,17]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[27]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,7,8,24]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[8,9,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,10,15,16]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[6,14]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[19]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[11,17]}],"complexes":["PAF1 complex","CPSF/CstF 3' processing complex"],"partners":["PAF1","LEO1","CTR9","RNF20","RNF40","SUV39H1","CTNNB1","SPT6"],"other_free_text":[]},"mechanistic_narrative":"CDC73 (parafibromin) is a scaffolding subunit of the PAF1 complex that couples RNA polymerase II transcription elongation to chromatin modification, mRNA 3′ end processing, and developmental signaling. Within the PAF1 complex, CDC73 associates with PAF1, LEO1, CTR9, and Spt6, and recruits the histone methyltransferase SUV39H1 to repress cyclin D1 and c-myc via H3K9 methylation, while also promoting H2B-K120 monoubiquitination through interaction with the RNF20/RNF40 E3 ligase [PMID:15632063, PMID:19906718, PMID:22021426, PMID:36928138]. CDC73 functions as a phosphorylation-regulated molecular switch: SHP2-mediated tyrosine dephosphorylation enables binding to β-catenin, Gli proteins, and NICD, converting CDC73 from a transcriptional repressor into a direct nuclear effector of Wnt, Hedgehog, and Notch signaling, whereas phosphorylation by PTK6 attenuates these activities [PMID:16630820, PMID:21726809, PMID:27650679]. Beyond transcription, CDC73 associates with CPSF/CstF to direct mRNA 3′ end maturation, controls replication-dependent histone mRNA processing, promotes homologous recombination repair through chromatin decondensation at DNA damage sites, and destabilizes cytoplasmic p53 mRNA via an eEF1Bγ/hSki8-containing complex [PMID:19136632, PMID:19908240, PMID:27462432, PMID:25388829]."},"prefetch_data":{"uniprot":{"accession":"Q6P1J9","full_name":"Parafibromin","aliases":["Cell division cycle protein 73 homolog","Hyperparathyroidism 2 protein"],"length_aa":531,"mass_kda":60.6,"function":"Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q6P1J9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CDC73","classification":"Common Essential","n_dependent_lines":1195,"n_total_lines":1208,"dependency_fraction":0.9892384105960265},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SSRP1","stoichiometry":4.0},{"gene":"TOP1","stoichiometry":4.0},{"gene":"CALM2","stoichiometry":0.2},{"gene":"CALM3","stoichiometry":0.2},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"SNRPA","stoichiometry":0.2},{"gene":"SNRPB","stoichiometry":0.2},{"gene":"SNRPC","stoichiometry":0.2},{"gene":"SRP9","stoichiometry":0.2},{"gene":"SUPT5H","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/CDC73","total_profiled":1310},"omim":[{"mim_id":"617343","title":"HYPERPARATHYROIDISM 4; HRPT4","url":"https://www.omim.org/entry/617343"},{"mim_id":"610507","title":"LEO1 HOMOLOG, PAF1/RNA POLYMERASE II COMPLEX COMPONENT; LEO1","url":"https://www.omim.org/entry/610507"},{"mim_id":"610506","title":"PAF1 HOMOLOG, PAF1/RNA POLYMERASE II COMPLEX COMPONENT; PAF1","url":"https://www.omim.org/entry/610506"},{"mim_id":"610071","title":"HYPERPARATHYROIDISM 3; HRPT3","url":"https://www.omim.org/entry/610071"},{"mim_id":"609366","title":"CTR9 HOMOLOG, PAF1/RNA POLYMERASE II COMPLEX COMPONENT; CTR9","url":"https://www.omim.org/entry/609366"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CDC73"},"hgnc":{"alias_symbol":["parafibromin","FIHP"],"prev_symbol":["C1orf28","HRPT2","HRPT1"]},"alphafold":{"accession":"Q6P1J9","domains":[{"cath_id":"-","chopping":"3-118","consensus_level":"high","plddt":87.6978,"start":3,"end":118},{"cath_id":"3.40.50.11990","chopping":"360-525","consensus_level":"high","plddt":86.6706,"start":360,"end":525}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6P1J9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6P1J9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6P1J9-F1-predicted_aligned_error_v6.png","plddt_mean":73.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDC73","jax_strain_url":"https://www.jax.org/strain/search?query=CDC73"},"sequence":{"accession":"Q6P1J9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6P1J9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6P1J9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6P1J9"}},"corpus_meta":[{"pmid":"12434154","id":"PMC_12434154","title":"HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12434154","citation_count":509,"is_preprint":false},{"pmid":"14585940","id":"PMC_14585940","title":"Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.","date":"2003","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14585940","citation_count":398,"is_preprint":false},{"pmid":"16630820","id":"PMC_16630820","title":"Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16630820","citation_count":258,"is_preprint":false},{"pmid":"12960210","id":"PMC_12960210","title":"HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours.","date":"2003","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12960210","citation_count":249,"is_preprint":false},{"pmid":"15632063","id":"PMC_15632063","title":"The parafibromin tumor suppressor protein is part of a human Paf1 complex.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15632063","citation_count":228,"is_preprint":false},{"pmid":"7717405","id":"PMC_7717405","title":"Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7717405","citation_count":187,"is_preprint":false},{"pmid":"15531515","id":"PMC_15531515","title":"Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15531515","citation_count":172,"is_preprint":false},{"pmid":"15475453","id":"PMC_15475453","title":"Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15475453","citation_count":161,"is_preprint":false},{"pmid":"15923622","id":"PMC_15923622","title":"The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15923622","citation_count":154,"is_preprint":false},{"pmid":"16931959","id":"PMC_16931959","title":"Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.","date":"2006","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16931959","citation_count":154,"is_preprint":false},{"pmid":"20052758","id":"PMC_20052758","title":"Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20052758","citation_count":134,"is_preprint":false},{"pmid":"15580289","id":"PMC_15580289","title":"Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15580289","citation_count":122,"is_preprint":false},{"pmid":"19136632","id":"PMC_19136632","title":"The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19136632","citation_count":114,"is_preprint":false},{"pmid":"14715834","id":"PMC_14715834","title":"Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14715834","citation_count":109,"is_preprint":false},{"pmid":"23166327","id":"PMC_23166327","title":"Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23166327","citation_count":101,"is_preprint":false},{"pmid":"17468190","id":"PMC_17468190","title":"Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?","date":"2007","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17468190","citation_count":100,"is_preprint":false},{"pmid":"19017757","id":"PMC_19017757","title":"Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19017757","citation_count":96,"is_preprint":false},{"pmid":"21726809","id":"PMC_21726809","title":"SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/21726809","citation_count":93,"is_preprint":false},{"pmid":"23293331","id":"PMC_23293331","title":"Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23293331","citation_count":93,"is_preprint":false},{"pmid":"16458039","id":"PMC_16458039","title":"HRPT2 gene alterations in ossifying fibroma of the jaws.","date":"2006","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16458039","citation_count":84,"is_preprint":false},{"pmid":"16487440","id":"PMC_16487440","title":"Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours.","date":"2006","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16487440","citation_count":82,"is_preprint":false},{"pmid":"17639063","id":"PMC_17639063","title":"Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.","date":"2007","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17639063","citation_count":80,"is_preprint":false},{"pmid":"22187299","id":"PMC_22187299","title":"Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism.","date":"2012","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22187299","citation_count":77,"is_preprint":false},{"pmid":"18987311","id":"PMC_18987311","title":"The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18987311","citation_count":75,"is_preprint":false},{"pmid":"18212049","id":"PMC_18212049","title":"Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18212049","citation_count":75,"is_preprint":false},{"pmid":"29324469","id":"PMC_29324469","title":"Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.","date":"2019","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29324469","citation_count":73,"is_preprint":false},{"pmid":"29040582","id":"PMC_29040582","title":"CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.","date":"2017","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29040582","citation_count":73,"is_preprint":false},{"pmid":"22021426","id":"PMC_22021426","title":"The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22021426","citation_count":71,"is_preprint":false},{"pmid":"16728578","id":"PMC_16728578","title":"Loss of parafibromin expression in a subset of parathyroid adenomas.","date":"2006","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16728578","citation_count":70,"is_preprint":false},{"pmid":"20463090","id":"PMC_20463090","title":"The Arabidopsis Paf1c complex component CDC73 participates in the modification of FLOWERING LOCUS C chromatin.","date":"2010","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20463090","citation_count":69,"is_preprint":false},{"pmid":"24145611","id":"PMC_24145611","title":"CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.","date":"2013","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/24145611","citation_count":68,"is_preprint":false},{"pmid":"17555500","id":"PMC_17555500","title":"Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17555500","citation_count":68,"is_preprint":false},{"pmid":"16720667","id":"PMC_16720667","title":"Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16720667","citation_count":68,"is_preprint":false},{"pmid":"19906718","id":"PMC_19906718","title":"The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19906718","citation_count":66,"is_preprint":false},{"pmid":"16989776","id":"PMC_16989776","title":"Parafibromin inhibits cancer cell growth and causes G1 phase arrest.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16989776","citation_count":64,"is_preprint":false},{"pmid":"16964291","id":"PMC_16964291","title":"Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16964291","citation_count":62,"is_preprint":false},{"pmid":"19522828","id":"PMC_19522828","title":"Parafibromin--functional insights.","date":"2009","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19522828","citation_count":60,"is_preprint":false},{"pmid":"22987117","id":"PMC_22987117","title":"CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.","date":"2012","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/22987117","citation_count":60,"is_preprint":false},{"pmid":"16995822","id":"PMC_16995822","title":"Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.","date":"2006","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/16995822","citation_count":58,"is_preprint":false},{"pmid":"15070940","id":"PMC_15070940","title":"Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15070940","citation_count":53,"is_preprint":false},{"pmid":"20473645","id":"PMC_20473645","title":"Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.","date":"2010","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20473645","citation_count":52,"is_preprint":false},{"pmid":"17314275","id":"PMC_17314275","title":"Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function.","date":"2007","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/17314275","citation_count":49,"is_preprint":false},{"pmid":"16116486","id":"PMC_16116486","title":"Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16116486","citation_count":48,"is_preprint":false},{"pmid":"18755853","id":"PMC_18755853","title":"Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism.","date":"2008","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18755853","citation_count":46,"is_preprint":false},{"pmid":"18436011","id":"PMC_18436011","title":"Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations.","date":"2008","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18436011","citation_count":46,"is_preprint":false},{"pmid":"16448924","id":"PMC_16448924","title":"Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation.","date":"2005","source":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/16448924","citation_count":46,"is_preprint":false},{"pmid":"9973288","id":"PMC_9973288","title":"Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q.","date":"1999","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9973288","citation_count":44,"is_preprint":false},{"pmid":"27650679","id":"PMC_27650679","title":"Dephosphorylated parafibromin is a transcriptional coactivator of the Wnt/Hedgehog/Notch pathways.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27650679","citation_count":44,"is_preprint":false},{"pmid":"23029104","id":"PMC_23029104","title":"Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029104","citation_count":42,"is_preprint":false},{"pmid":"19368795","id":"PMC_19368795","title":"The role of Parafibromin/Hyrax as a nuclear Gli/Ci-interacting protein in Hedgehog target gene control.","date":"2009","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/19368795","citation_count":41,"is_preprint":false},{"pmid":"15613436","id":"PMC_15613436","title":"A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15613436","citation_count":40,"is_preprint":false},{"pmid":"17130827","id":"PMC_17130827","title":"Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17130827","citation_count":39,"is_preprint":false},{"pmid":"20363855","id":"PMC_20363855","title":"PLANT HOMOLOGOUS TO PARAFIBROMIN is a component of the PAF1 complex and assists in regulating expression of genes within H3K27ME3-enriched chromatin.","date":"2010","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20363855","citation_count":39,"is_preprint":false},{"pmid":"30227954","id":"PMC_30227954","title":"Transcriptional Co-activator Functions of YAP and TAZ Are Inversely Regulated by Tyrosine Phosphorylation Status of Parafibromin.","date":"2018","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/30227954","citation_count":38,"is_preprint":false},{"pmid":"24823466","id":"PMC_24823466","title":"CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24823466","citation_count":38,"is_preprint":false},{"pmid":"32590342","id":"PMC_32590342","title":"Genotype of CDC73 germline mutation determines risk of parathyroid cancer.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32590342","citation_count":36,"is_preprint":false},{"pmid":"30923346","id":"PMC_30923346","title":"Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.","date":"2019","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/30923346","citation_count":36,"is_preprint":false},{"pmid":"21837707","id":"PMC_21837707","title":"Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21837707","citation_count":35,"is_preprint":false},{"pmid":"16061557","id":"PMC_16061557","title":"Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism.","date":"2005","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16061557","citation_count":35,"is_preprint":false},{"pmid":"21221636","id":"PMC_21221636","title":"Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.","date":"2011","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21221636","citation_count":32,"is_preprint":false},{"pmid":"20026646","id":"PMC_20026646","title":"CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.","date":"2010","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20026646","citation_count":32,"is_preprint":false},{"pmid":"27462432","id":"PMC_27462432","title":"A genome-wide IR-induced RAD51 foci RNAi screen identifies CDC73 involved in chromatin remodeling for DNA repair.","date":"2015","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27462432","citation_count":32,"is_preprint":false},{"pmid":"21790700","id":"PMC_21790700","title":"Identification of the first germline HRPT2 whole-gene deletion in a patient with primary hyperparathyroidism.","date":"2012","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21790700","citation_count":31,"is_preprint":false},{"pmid":"21652691","id":"PMC_21652691","title":"CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum.","date":"2011","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21652691","citation_count":30,"is_preprint":false},{"pmid":"22932087","id":"PMC_22932087","title":"Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.","date":"2012","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/22932087","citation_count":30,"is_preprint":false},{"pmid":"27490759","id":"PMC_27490759","title":"Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.","date":"2017","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/27490759","citation_count":30,"is_preprint":false},{"pmid":"18217513","id":"PMC_18217513","title":"Aberrant methylation of the HRPT2 gene in parathyroid carcinoma.","date":"2007","source":"The Annals of otology, rhinology, and laryngology","url":"https://pubmed.ncbi.nlm.nih.gov/18217513","citation_count":29,"is_preprint":false},{"pmid":"32863766","id":"PMC_32863766","title":"Circ_0000140 restrains the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma through upregulating CDC73 via sponging miR-182-5p.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32863766","citation_count":29,"is_preprint":false},{"pmid":"19908240","id":"PMC_19908240","title":"The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA.","date":"2010","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19908240","citation_count":29,"is_preprint":false},{"pmid":"18687124","id":"PMC_18687124","title":"The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3.","date":"2008","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18687124","citation_count":28,"is_preprint":false},{"pmid":"17639062","id":"PMC_17639062","title":"Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation.","date":"2007","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17639062","citation_count":28,"is_preprint":false},{"pmid":"25388829","id":"PMC_25388829","title":"Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25388829","citation_count":27,"is_preprint":false},{"pmid":"20304979","id":"PMC_20304979","title":"Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome.","date":"2010","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20304979","citation_count":27,"is_preprint":false},{"pmid":"17404568","id":"PMC_17404568","title":"Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17404568","citation_count":27,"is_preprint":false},{"pmid":"24257751","id":"PMC_24257751","title":"Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24257751","citation_count":27,"is_preprint":false},{"pmid":"24842573","id":"PMC_24842573","title":"Characterization of a new CDC73 missense mutation that impairs Parafibromin expression and nucleolar localization.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24842573","citation_count":26,"is_preprint":false},{"pmid":"17118068","id":"PMC_17118068","title":"Immunohistochemical assessment of parafibromin in mouse and human tissues.","date":"2006","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/17118068","citation_count":25,"is_preprint":false},{"pmid":"21324824","id":"PMC_21324824","title":"Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk.","date":"2011","source":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","url":"https://pubmed.ncbi.nlm.nih.gov/21324824","citation_count":25,"is_preprint":false},{"pmid":"36928138","id":"PMC_36928138","title":"Spt6 directly interacts with Cdc73 and is required for Paf1 complex occupancy at active genes in Saccharomyces cerevisiae.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/36928138","citation_count":23,"is_preprint":false},{"pmid":"19474519","id":"PMC_19474519","title":"Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.","date":"2009","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19474519","citation_count":23,"is_preprint":false},{"pmid":"16001331","id":"PMC_16001331","title":"HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome.","date":"2005","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/16001331","citation_count":23,"is_preprint":false},{"pmid":"24716902","id":"PMC_24716902","title":"Familial isolated primary hyperparathyroidism/hyperparathyroidism-jaw tumour syndrome caused by germline gross deletion or point mutations of CDC73 gene in Chinese.","date":"2014","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24716902","citation_count":22,"is_preprint":false},{"pmid":"21197463","id":"PMC_21197463","title":"Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse?","date":"2010","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21197463","citation_count":21,"is_preprint":false},{"pmid":"35551175","id":"PMC_35551175","title":"UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35551175","citation_count":20,"is_preprint":false},{"pmid":"27658992","id":"PMC_27658992","title":"CDC73 gene mutations in sporadic ossifying fibroma of the jaws.","date":"2016","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27658992","citation_count":20,"is_preprint":false},{"pmid":"30452964","id":"PMC_30452964","title":"CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors.","date":"2018","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/30452964","citation_count":19,"is_preprint":false},{"pmid":"23453027","id":"PMC_23453027","title":"Assessing the contribution of HRPT2 to the pathogenesis of jaw fibrous dysplasia, ossifying fibroma, and osteosarcoma.","date":"2013","source":"Oral surgery, oral medicine, oral pathology and oral radiology","url":"https://pubmed.ncbi.nlm.nih.gov/23453027","citation_count":19,"is_preprint":false},{"pmid":"29142233","id":"PMC_29142233","title":"Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29142233","citation_count":19,"is_preprint":false},{"pmid":"27544721","id":"PMC_27544721","title":"A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature.","date":"2016","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/27544721","citation_count":19,"is_preprint":false},{"pmid":"26742426","id":"PMC_26742426","title":"Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26742426","citation_count":19,"is_preprint":false},{"pmid":"21521290","id":"PMC_21521290","title":"Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation.","date":"2011","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21521290","citation_count":18,"is_preprint":false},{"pmid":"23029479","id":"PMC_23029479","title":"Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029479","citation_count":17,"is_preprint":false},{"pmid":"18063086","id":"PMC_18063086","title":"Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism.","date":"2007","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18063086","citation_count":17,"is_preprint":false},{"pmid":"21360064","id":"PMC_21360064","title":"Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses.","date":"2011","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21360064","citation_count":17,"is_preprint":false},{"pmid":"26675091","id":"PMC_26675091","title":"The Role of Parafibromin, Galectin-3, HBME-1, 
and Ki-67 in the Differential Diagnosis of Parathyroid Tumors.","date":"2015","source":"Oman medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26675091","citation_count":16,"is_preprint":false},{"pmid":"21732217","id":"PMC_21732217","title":"Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors.","date":"2011","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21732217","citation_count":16,"is_preprint":false},{"pmid":"19092296","id":"PMC_19092296","title":"Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.","date":"2008","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19092296","citation_count":16,"is_preprint":false},{"pmid":"29320491","id":"PMC_29320491","title":"Cdc73 suppresses genome instability by mediating telomere homeostasis.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29320491","citation_count":16,"is_preprint":false},{"pmid":"20339377","id":"PMC_20339377","title":"Cytoplasmic polyadenylation element binding protein is a conserved target of tumor suppressor HRPT2/CDC73.","date":"2010","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/20339377","citation_count":15,"is_preprint":false},{"pmid":"30541148","id":"PMC_30541148","title":"Regulation of ATR activity via the RNA polymerase II associated factors CDC73 and PNUTS-PP1.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30541148","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51464,"output_tokens":7222,"usd":0.131361},"stage2":{"model":"claude-opus-4-6","input_tokens":10876,"output_tokens":4810,"usd":0.261945},"total_usd":0.393306,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"Parafibromin (CDC73) is a component of the human PAF1 complex, physically associating with PAF1, LEO1, and CTR9 homologs, and co-purifies with non-phosphorylated, Ser2-phosphorylated, and Ser5-phosphorylated forms of the RNA polymerase II large subunit. Cotransfection data suggest parafibromin can interact with a histone methyltransferase complex that methylates histone H3 on lysine 4.\",\n      \"method\": \"Cellular purification of parafibromin followed by mass spectrometry identification of associated proteins; co-immunoprecipitation; immunofluorescence; cotransfection assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP and mass spectrometry, replicated in two independent papers (PMID 15632063, 15923622)\",\n      \"pmids\": [\"15632063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Parafibromin physically interacts with human orthologs of yeast Paf1 complex components (PAF1, LEO1, CTR9) involved in transcription elongation and 3' end processing, and associates with RNA polymerase II large subunit phosphorylated on Ser5 or Ser2 of its CTD. These interactions depend on a C-terminal domain of parafibromin deleted in ~80% of clinically relevant mutations. RNAi-induced downregulation of parafibromin promotes entry into S phase.\",\n      \"method\": \"Co-immunoprecipitation; RNAi knockdown with cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with multiple subunits, functional RNAi phenotype, replicated across labs\",\n      \"pmids\": [\"15923622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Drosophila Hyrax (parafibromin ortholog) and human Parafibromin are required for nuclear transduction of the Wnt/Wg signal and bind directly to the C-terminal region of beta-catenin/Armadillo. The transactivation potential of Parafibromin/Hyrax depends on recruitment of Pygopus to beta-catenin/Armadillo, identifying the PAF1 complex as a direct nuclear effector of Wnt signaling.\",\n      \"method\": \"Genetic epistasis in Drosophila; direct binding assays; co-immunoprecipitation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic epistasis in Drosophila combined with direct binding assays; validated in mammalian cells; highly cited\",\n      \"pmids\": [\"16630820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Transient overexpression of wild-type parafibromin, but not its Leu64Pro missense mutant, inhibits cell proliferation and blocks expression of cyclin D1, a key cell cycle regulator, demonstrating a functional role for parafibromin in repressing cyclin D1.\",\n      \"method\": \"Transient overexpression; cell proliferation assay; Western blot for cyclin D1\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression with mutant control and defined molecular readout, single lab\",\n      \"pmids\": [\"15580289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Parafibromin contains a functional monopartite nuclear localization signal (NLS) at residues 136-139 (KKXR) that is evolutionarily conserved and critical for nuclear localization; deletion or mutation of this NLS abolishes nuclear targeting.\",\n      \"method\": \"Site-directed mutagenesis; confocal fluorescence microscopy of GFP-tagged constructs; Western blot of nuclear/cytoplasmic fractions\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis with direct imaging and fractionation, confirmed by two independent studies (PMID 16964291, 16116486)\",\n      \"pmids\": [\"16964291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A functional bipartite nuclear localization signal (NLS) in parafibromin was identified at residues 125-139 (KRAADEVLAEAKKPR); the C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. Specific HRPT2 mutations that truncate parafibromin upstream of or within this NLS disrupt nuclear localization.\",\n      \"method\": \"Expression of GFP-tagged wild-type and mutant parafibromin; confocal fluorescence microscopy\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with direct imaging, replicated by PMID 16964291\",\n      \"pmids\": [\"16116486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CDC73 (Cdc73/parafibromin) physically associates with the cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CstF) complexes required for mRNA 3' end maturation. Immunodepletion of the Cdc73-CPSF-CstF complex abolishes 3' mRNA processing in vitro. CDC73 siRNA leads to decreased INTS6 mRNA abundance and decreased CPSF/CstF association with the INTS6 locus.\",\n      \"method\": \"Co-immunoprecipitation; in vitro mRNA 3' processing assay with immunodepletion; siRNA knockdown; microarray; chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution/immunodepletion with multiple orthogonal methods\",\n      \"pmids\": [\"19136632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Parafibromin inhibits cell proliferation and represses the c-myc proto-oncogene through both c-myc protein stabilization inhibition and promoter repression via the PAF1 complex. Chromatin immunoprecipitation demonstrates direct occupancy of the c-myc promoter by parafibromin and other PAF1 complex subunits. Knockdown of c-myc blocks the proliferative effect of parafibromin/Paf1 RNAi.\",\n      \"method\": \"RNAi knockdown; cell proliferation assay; ChIP; Western blot; reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct promoter occupancy plus epistasis through c-myc knockdown rescue, multiple orthogonal methods\",\n      \"pmids\": [\"18987311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Parafibromin interacts with the histone methyltransferase SUV39H1 via its central region (residues 128-227), recruits SUV39H1 to the promoter and coding regions of cyclin D1, and induces H3 K9 methylation (but not H3 K4 methylation) at the cyclin D1 locus, thereby repressing cyclin D1 expression.\",\n      \"method\": \"Co-immunoprecipitation; ChIP; RNAi knockdown; reporter assay; deletion mapping\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with direct mechanistic readout, co-IP with domain mapping, RNAi epistasis\",\n      \"pmids\": [\"19906718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CDC73 interacts with the E3 ubiquitin ligase ring finger proteins RNF20 and RNF40 (which form a heterodimer catalyzing monoubiquitination of histone H2B at K120). CDC73 binds to discrete but closely located residues on RNF20 and RNF40. Loss of nuclear CDC73 in vitro (by siRNA) or in CDC73-mutant parathyroid tumors significantly reduces H2B-K120 monoubiquitination, while H3-K4me3 remains unchanged.\",\n      \"method\": \"Yeast two-hybrid screen; co-immunoprecipitation; siRNA knockdown; immunohistochemistry of tumor tissue; Western blot for histone modifications\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid plus Co-IP plus in vitro knockdown plus in vivo tumor analysis, multiple orthogonal methods\",\n      \"pmids\": [\"22021426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SHP2 phosphatase dephosphorylates parafibromin on tyrosine residues. Tyrosine dephosphorylation by SHP2 enables parafibromin to stably bind beta-catenin, thereby activating Wnt target genes including cyclin D1 and c-myc, overriding the parafibromin/SUV39H1-mediated transrepression. Thus, SHP2 governs the opposing tumor suppressor vs. oncogenic functions of parafibromin.\",\n      \"method\": \"In vitro phosphatase assay; co-immunoprecipitation; reporter assay; Western blot; cell-based functional assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro phosphatase assay plus Co-IP plus functional reporter assays with mechanistic dissection\",\n      \"pmids\": [\"21726809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nuclear localization of parafibromin is required for its proapoptotic activity. Mutation of both a dominant bipartite NLS and a secondary NLS in the NH2-terminal region nearly abolishes nuclear targeting, significantly impairs association with endogenous Paf1 and Leo1, and abolishes the ability of overexpressed parafibromin to induce apoptosis. Endogenous parafibromin knockdown by RNAi inhibits basal apoptosis and camptothecin-induced apoptosis.\",\n      \"method\": \"Site-directed mutagenesis; co-immunoprecipitation; confocal fluorescence microscopy; RNAi; apoptosis assays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis linking NLS to Paf1 binding and functional apoptosis phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"17314275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Parafibromin interacts with muscle alpha-actinins (actinin-2 and actinin-3) but not non-muscle alpha-actinins, through its N-terminal region. Parafibromin can bundle/cross-link actin filaments in actin sedimentation assays. In differentiated myotubes, parafibromin co-localizes with actinins in the cytoplasm, whereas in proliferating myoblasts it is predominantly nuclear.\",\n      \"method\": \"Yeast two-hybrid; GST pull-down; co-immunoprecipitation; actin sedimentation assay; confocal microscopy\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and GST pull-down plus functional actin assay, single lab\",\n      \"pmids\": [\"18687124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Parafibromin, as a transcription factor associated with the PAF complex, directly regulates genes involved in cell growth and survival (H19, Igf1, Igf2, Igfbp4, Hmga1, Hmga2, Hmgcs2) as shown by ChIP. Conditional homozygous deletion of Hrpt2 in mice causes embryonic lethality by E6.5, apoptosis in embryonic fibroblasts, and cachexia/death in adults.\",\n      \"method\": \"Conditional knockout mouse; cDNA microarray; chromatin immunoprecipitation; semi-quantitative RT-PCR; MEF culture with Cre-mediated deletion\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO mouse with ChIP and defined molecular readouts, multiple orthogonal methods\",\n      \"pmids\": [\"18212049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Parafibromin regulates 3' processing of replication-dependent histone mRNA. Downregulation of parafibromin by siRNA or in vivo CDC73 mutations leads to uncleaved histone mRNA with polyadenylated tails, demonstrating a posttranscriptional role in histone mRNA 3' end processing.\",\n      \"method\": \"siRNA knockdown; RNA analysis (RT-PCR, Northern); analysis of tumor samples with in vivo mutations\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro knockdown plus in vivo mutation-correlated phenotype, single lab\",\n      \"pmids\": [\"19908240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Dephosphorylated parafibromin competitively interacts with beta-catenin and Gli1, potentiating transactivation of Wnt- and Hedgehog-target genes in a mutually exclusive manner. Parafibromin also binds to the Notch intracellular domain (NICD), enabling concerted Wnt- and Notch-target gene activation. Tyrosine dephosphorylation by SHP2 potentiates and phosphorylation by PTK6 kinase attenuates these functions. Acute parafibromin loss in mouse intestine disorganizes epithelial architecture.\",\n      \"method\": \"Co-immunoprecipitation; reporter assays; conditional mouse knockout; immunofluorescence; cell-based assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple Co-IPs with competitive binding, reporter assays, in vivo mouse loss-of-function with defined epithelial phenotype\",\n      \"pmids\": [\"27650679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Parafibromin/Hyrax acts as a positive component of Hedgehog signaling by directly binding Region 1 (the Su(fu) interaction domain) in the N-terminus of all three Gli proteins and Ci. Parafibromin forms a complex with Gli1, Gli2, and Gli3. RNAi knockdown of Parafibromin in mammalian cells diminishes transcriptional activity of Gli1 and Gli2.\",\n      \"method\": \"Drosophila genetic epistasis; RNAi in cell culture; co-immunoprecipitation; reporter assay\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis plus Co-IP plus RNAi functional assay, single lab\",\n      \"pmids\": [\"19368795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cytoplasmic parafibromin/hCdc73 physically associates with mature p53 mRNA in the cytoplasm and facilitates its degradation, thereby controlling p53-mediated apoptosis. Cytoplasmic hCdc73 interacts with eEF1Bγ and hSki8; this interaction is required to bind and destabilize p53 mRNA. A cancer-associated K34Q mutant shows enhanced p53 mRNA binding and reduces p53 expression.\",\n      \"method\": \"RNA immunoprecipitation (RIP); co-immunoprecipitation; mRNA stability assay; mutagenesis; cell viability assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — RIP identifying mRNA substrate, Co-IP of protein complex, mechanistic mutagenesis with functional readout\",\n      \"pmids\": [\"25388829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"YAP and TAZ transcriptional co-activator functions are inversely regulated by parafibromin's tyrosine phosphorylation state. Tyrosine-dephosphorylated parafibromin stimulates TAZ and beta-catenin cooperatively; tyrosine-phosphorylated parafibromin selectively activates YAP without interacting with beta-catenin.\",\n      \"method\": \"Co-immunoprecipitation; reporter assay; mutagenesis; cell-based functional assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with phosphorylation-state dependency and reporter functional assays, single lab\",\n      \"pmids\": [\"30227954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CDC73 interacts with components of the SCF/Cullin and INO80/NuA4 chromatin-remodeling complexes to promote histone ubiquitination, and is required for local chromatin decondensation at sites of DNA damage to promote homologous recombination repair. This function is related to but independent of CDC73's role in transcriptional elongation.\",\n      \"method\": \"Genome-wide siRNA screen; co-immunoprecipitation; RAD51 foci assay; HR repair assay; RPA foci assay\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide screen with Co-IP and functional HR assay, single lab\",\n      \"pmids\": [\"27462432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDC73 interacts with RNA polymerase II in a phospho-CTD (carboxy-terminal domain)-dependent manner and is required for high ATR signaling, R-loop formation, and activation of the G2 checkpoint after PNUTS-PP1 depletion. ATR, RNAPII, and CDC73 co-immunoprecipitate.\",\n      \"method\": \"Co-immunoprecipitation; siRNA knockdown; ATR signaling assays; R-loop detection; checkpoint assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with functional checkpoint and R-loop phenotype, single lab\",\n      \"pmids\": [\"30541148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"UBR5 (HECT-domain E3 ubiquitin ligase) polyubiquitinates CDC73 at Lys243, Lys247, and Lys257, leading to its proteasomal degradation. This ubiquitination depends on the non-phosphorylation state of CDC73 at Ser465. CDC73 acts as a molecular switch to modulate UBR5's pro-tumor activities in triple-negative breast cancer.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assay; site-directed mutagenesis; Western blot; in vivo xenograft\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct ubiquitination assay with site-specific mutagenesis and functional in vivo data, single lab\",\n      \"pmids\": [\"35551175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of the N-terminal domain of human CDC73 (residues 1-111, hCDC73-NTD) at 1.02 Å resolution reveals a novel protein fold with an extended hydrophobic groove. Most pathogenic HPT-JT-associated missense mutations disrupt folding of the hydrophobic core of hCDC73-NTD, while others (e.g., K34Q) reduce thermostability.\",\n      \"method\": \"X-ray crystallography; limited proteolysis; biochemical thermostability assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure at atomic resolution with biochemical validation and mutant analysis\",\n      \"pmids\": [\"29142233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LEOPARD syndrome-associated SHP2 mutants (Y279C, T468M, Q506P, Q510E) exhibit substantially reduced phosphatase activity toward tyrosine-phosphorylated parafibromin in an in vitro phosphatase assay, demonstrating parafibromin as a bona fide SHP2 substrate.\",\n      \"method\": \"In vitro phosphatase assay using tyrosine-phosphorylated parafibromin substrate; SHP2 mutant panel\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay with multiple mutants, confirms parafibromin as SHP2 substrate\",\n      \"pmids\": [\"26742426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In yeast, Cdc73 directly interacts with the transcription elongation factor Spt6 (through Spt6's tandem SH2 domain) and with the largest subunit of RNA polymerase II. These interactions can be detected in vitro. Rapid depletion of Spt6 dissociates Paf1 from chromatin and alters Paf1C-dependent histone modifications genome-wide. A central 105 amino acid region of Cdc73 is necessary and sufficient for binding Ctr9 and nuclear localization, and suppresses genome instability.\",\n      \"method\": \"Site-specific protein cross-linking in yeast cells; in vitro binding assay; auxin-inducible degron (rapid depletion); ChIP-seq; deletion analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo cross-linking identifying direct contacts, confirmed in vitro, combined with genome-wide ChIP and rapid depletion\",\n      \"pmids\": [\"36928138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Parafibromin regulates the mRNA stability of CPEB1 (cytoplasmic polyadenylation element binding protein). Parafibromin occupies the CPEB1 locus as shown by ChIP. A genetic interaction between hyx/parafibromin and orb/CPEB was identified through Drosophila double heterozygote screens.\",\n      \"method\": \"Drosophila genetic screen; siRNA knockdown in mammalian cells; Western blot; chromatin immunoprecipitation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic interaction confirmed by ChIP and mammalian knockdown, single lab\",\n      \"pmids\": [\"20339377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A central 105 amino acid region of Cdc73 in yeast is necessary and sufficient for suppressing gross chromosomal rearrangements, binding to the Paf1 complex via Ctr9, and nuclear localization. Loss of Cdc73 causes increased telomere dysfunction and accumulation of chromosomal rearrangements, mediated by partial telomere dysfunction.\",\n      \"method\": \"GCR assay; deletion analysis; co-immunoprecipitation; telomere length analysis; telomeric silencing assay; whole genome sequencing\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — yeast deletion analysis with functional GCR assay and telomere assays, single lab\",\n      \"pmids\": [\"29320491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Parafibromin deficiency (via L95P missense mutation) causes defective nucleolar localization and dominant-negative interference with endogenous parafibromin. The L95P mutant retains the ability to assemble with endogenous PAF1 complex components but is expressed at lower levels, is not rescued by proteasome inhibition, and enhances cell cycle progression and survival when transfected.\",\n      \"method\": \"Transfection; co-immunoprecipitation; confocal microscopy; cell cycle analysis; proteasome inhibitor treatment; flow cytometry\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional mutagenesis with mechanistic imaging and Co-IP, single lab\",\n      \"pmids\": [\"20304979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MicroRNA-155 (miR-155) directly targets the 3'-UTR of CDC73 mRNA, negatively regulating CDC73 expression. Ectopic miR-155 expression dramatically reduces CDC73 levels and enhances cell viability/reduces apoptosis; delivery of antagomir-155 increases CDC73 levels, decreases cell viability, and causes xenograft regression.\",\n      \"method\": \"miRNA overexpression/antagomir delivery; 3'-UTR reporter assay; Western blot; in vivo xenograft\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional miRNA-target interaction confirmed by rescue and in vivo data, single lab\",\n      \"pmids\": [\"23166327\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDC73/Parafibromin is a nuclear (and in some contexts cytoplasmic) component of the RNA polymerase II-associated PAF1 complex that regulates transcription elongation, histone modifications (H3K4 methylation, H2B-K120 monoubiquitination via RNF20/RNF40, and H3K9 methylation via SUV39H1), and mRNA 3' end processing (via CPSF/CstF); it directly represses oncogenes cyclin D1 and c-myc, is a direct transcriptional effector of Wnt, Hedgehog, and Notch signaling through physical binding to beta-catenin, Gli proteins, and NICD respectively, and its tumor suppressor vs. oncogenic activities are switched by SHP2/PTK6-regulated tyrosine phosphorylation/dephosphorylation; its stability is regulated by UBR5-mediated polyubiquitination, and its loss causes genome instability through defective telomere maintenance and impaired homologous recombination repair.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CDC73 (parafibromin) is a scaffolding subunit of the PAF1 complex that couples RNA polymerase II transcription elongation to chromatin modification, mRNA 3′ end processing, and developmental signaling. Within the PAF1 complex, CDC73 associates with PAF1, LEO1, CTR9, and Spt6, and recruits the histone methyltransferase SUV39H1 to repress cyclin D1 and c-myc via H3K9 methylation, while also promoting H2B-K120 monoubiquitination through interaction with the RNF20/RNF40 E3 ligase [PMID:15632063, PMID:19906718, PMID:22021426, PMID:36928138]. CDC73 functions as a phosphorylation-regulated molecular switch: SHP2-mediated tyrosine dephosphorylation enables binding to β-catenin, Gli proteins, and NICD, converting CDC73 from a transcriptional repressor into a direct nuclear effector of Wnt, Hedgehog, and Notch signaling, whereas phosphorylation by PTK6 attenuates these activities [PMID:16630820, PMID:21726809, PMID:27650679]. Beyond transcription, CDC73 associates with CPSF/CstF to direct mRNA 3′ end maturation, controls replication-dependent histone mRNA processing, promotes homologous recombination repair through chromatin decondensation at DNA damage sites, and destabilizes cytoplasmic p53 mRNA via an eEF1Bγ/hSki8-containing complex [PMID:19136632, PMID:19908240, PMID:27462432, PMID:25388829].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying CDC73 as a bona fide PAF1 complex subunit resolved how a tumor suppressor gene product interfaces with the RNA Pol II transcription elongation machinery.\",\n      \"evidence\": \"Mass spectrometry of purified parafibromin complexes and reciprocal co-immunoprecipitation with PAF1, LEO1, CTR9, and phospho-Pol II CTD forms in human cells, replicated across two independent labs\",\n      \"pmids\": [\"15632063\", \"15923622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of human PAF1 complex not determined\", \"Which CDC73 surfaces directly contact each subunit was unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that overexpressed wild-type but not mutant parafibromin represses cyclin D1 and inhibits proliferation established CDC73's tumor-suppressive mechanism at a defined target gene.\",\n      \"evidence\": \"Transient overexpression with L64P mutant control, cyclin D1 Western blot, and cell proliferation assay\",\n      \"pmids\": [\"15580289\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression system; endogenous loss-of-function validation of cyclin D1 regulation was lacking\", \"Mechanism of promoter-level repression not yet dissected\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapping a nuclear localization signal in parafibromin explained why clinically observed truncating mutations cause loss of function by mislocalizing the protein.\",\n      \"evidence\": \"GFP-tagged mutagenesis with confocal microscopy and nuclear/cytoplasmic fractionation, confirmed independently\",\n      \"pmids\": [\"16116486\", \"16964291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cytoplasmic parafibromin retains any function was unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showing that parafibromin directly binds β-catenin and is required for Wnt nuclear transduction repositioned CDC73 from a general transcription factor to a signal-specific transcriptional effector.\",\n      \"evidence\": \"Drosophila genetic epistasis with Hyrax, direct binding assays, and co-immunoprecipitation with β-catenin in mammalian cells\",\n      \"pmids\": [\"16630820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether binding is constitutive or signal-regulated was not known\", \"Structural basis of β-catenin–parafibromin interface unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linking nuclear localization to both PAF1 complex assembly and proapoptotic activity demonstrated that CDC73's tumor suppression requires its nuclear role rather than cytoplasmic functions.\",\n      \"evidence\": \"NLS mutagenesis with co-immunoprecipitation for PAF1/LEO1 and apoptosis assays upon RNAi knockdown\",\n      \"pmids\": [\"17314275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream apoptotic pathway not fully delineated\", \"Whether a cytoplasmic pool has independent pro-survival functions was unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"ChIP-based identification of c-myc as a direct PAF1-complex-occupied target gene, combined with epistatic rescue by c-myc knockdown, provided the first complete transcriptional circuit linking CDC73 loss to oncogene derepression and proliferation.\",\n      \"evidence\": \"ChIP for PAF1 complex subunits at the c-myc promoter; RNAi epistasis showing c-myc knockdown blocks parafibromin-depletion-induced proliferation\",\n      \"pmids\": [\"18987311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism distinguishing repression at c-myc from activation at Wnt targets not clarified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Conditional knockout in mice proved CDC73 is essential for embryonic viability and identified downstream growth/survival gene targets (Igf axis, Hmga genes) by ChIP, moving from cell-line studies to organismal requirement.\",\n      \"evidence\": \"Conditional Hrpt2 knockout mouse with embryonic lethality at E6.5; cDNA microarray and ChIP in MEFs\",\n      \"pmids\": [\"18212049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific requirements beyond early embryogenesis incompletely mapped\", \"Relative contribution of individual target genes to lethality unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that CDC73 physically associates with CPSF/CstF and is required for mRNA 3′ end processing in vitro expanded its function beyond transcription elongation to co-transcriptional RNA maturation.\",\n      \"evidence\": \"Co-immunoprecipitation, immunodepletion abolishing in vitro 3′ processing, siRNA with ChIP showing loss of CPSF/CstF at a target locus\",\n      \"pmids\": [\"19136632\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDC73 directly contacts CPSF/CstF or acts via PAF1 complex bridging was not resolved\", \"Genome-wide scope of 3′ processing dependency unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of SUV39H1 as a CDC73-recruited histone methyltransferase that deposits H3K9me at the cyclin D1 locus provided a direct epigenetic mechanism for CDC73-mediated gene repression distinct from H3K4 methylation.\",\n      \"evidence\": \"Co-immunoprecipitation with domain mapping; ChIP showing H3K9 methylation at cyclin D1 promoter/coding regions dependent on parafibromin\",\n      \"pmids\": [\"19906718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SUV39H1 recruitment is gene-specific or genome-wide was unknown\", \"H3K9me reader proteins downstream were not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Binding of parafibromin to all three Gli proteins and Drosophila Ci placed CDC73 as a shared nuclear effector of both Wnt and Hedgehog signaling pathways.\",\n      \"evidence\": \"Drosophila genetic epistasis; co-immunoprecipitation with Gli1/2/3; RNAi reducing Gli transcriptional activity\",\n      \"pmids\": [\"19368795\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Wnt and Hedgehog inputs compete for CDC73 binding was unresolved\", \"In vivo mammalian Hedgehog phenotype of CDC73 loss not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapping a minimal 105-aa Cdc73 region sufficient for Ctr9 binding, nuclear localization, and suppression of gross chromosomal rearrangements linked PAF1 complex integrity to genome stability through telomere maintenance.\",\n      \"evidence\": \"Yeast GCR assay, deletion analysis, co-immunoprecipitation with Ctr9, telomere length and silencing assays\",\n      \"pmids\": [\"29320491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between telomere dysfunction and GCR was correlative\", \"Whether mammalian CDC73 loss also causes telomere defects was not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that SHP2-mediated tyrosine dephosphorylation of parafibromin switches it from a transcriptional repressor to a β-catenin-dependent transactivator provided the key regulatory logic explaining CDC73's dual tumor suppressor/oncogene behavior.\",\n      \"evidence\": \"In vitro SHP2 phosphatase assay; co-immunoprecipitation showing phosphorylation-dependent β-catenin binding; reporter assays\",\n      \"pmids\": [\"21726809\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tyrosine residue(s) phosphorylated on CDC73 not identified\", \"Kinase responsible for CDC73 tyrosine phosphorylation was unknown at this point\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showing that CDC73 interacts with the RNF20/RNF40 E3 ligase and is required for H2B-K120 monoubiquitination in cells and tumors established a second chromatin modification axis controlled by CDC73, distinct from H3K9 methylation.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, siRNA, immunohistochemistry of CDC73-mutant parathyroid tumors\",\n      \"pmids\": [\"22021426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDC73 stimulates RNF20/RNF40 enzymatic activity or merely recruits it was unclear\", \"Genome-wide pattern of H2Bub1 loss upon CDC73 mutation not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that cytoplasmic parafibromin binds mature p53 mRNA via an eEF1Bγ/hSki8 complex and promotes its degradation revealed a post-transcriptional, non-PAF1-complex function that explains how cytoplasmic CDC73 can be oncogenic.\",\n      \"evidence\": \"RNA immunoprecipitation identifying p53 mRNA; co-immunoprecipitation with eEF1Bγ and hSki8; mRNA stability assays; K34Q cancer mutant with enhanced p53 mRNA binding\",\n      \"pmids\": [\"25388829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other mRNAs are similarly regulated by cytoplasmic CDC73 was not addressed\", \"Structural basis of CDC73–mRNA interaction unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"A genome-wide screen placing CDC73 in homologous recombination repair through chromatin decondensation at damage sites broadened CDC73's roles beyond transcription to DNA damage response.\",\n      \"evidence\": \"Genome-wide siRNA screen; RAD51/RPA foci assays; HR reporter assay; co-immunoprecipitation with SCF/Cullin and INO80/NuA4 components\",\n      \"pmids\": [\"27462432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the HR function depends on PAF1 complex or is CDC73-autonomous was not resolved\", \"Direct DNA-damage-site recruitment mechanism unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Confirming parafibromin as a direct SHP2 substrate using LEOPARD syndrome mutants with reduced phosphatase activity validated the phosphorylation switch model with disease-relevant mutations.\",\n      \"evidence\": \"In vitro phosphatase assay with panel of LEOPARD-associated SHP2 mutants and tyrosine-phosphorylated parafibromin substrate\",\n      \"pmids\": [\"26742426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance in LEOPARD syndrome patients not tested\", \"Which tyrosine residues on CDC73 are dephosphorylated still unidentified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that dephosphorylated parafibromin competitively binds β-catenin, Gli1, and NICD in a mutually exclusive manner, with PTK6 as the opposing kinase to SHP2, unified Wnt, Hedgehog, and Notch nuclear effector functions under a single phospho-switch.\",\n      \"evidence\": \"Co-immunoprecipitation with competitive binding; reporter assays; conditional mouse intestinal knockout with epithelial disorganization\",\n      \"pmids\": [\"27650679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for mutually exclusive binding not determined\", \"In vivo consequences for Hedgehog and Notch targets in the intestine not individually dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The 1.02 Å crystal structure of the CDC73 N-terminal domain revealed a novel fold and explained how HPT-JT-associated missense mutations destabilize the protein, providing the first structural framework for interpreting clinical mutations.\",\n      \"evidence\": \"X-ray crystallography at atomic resolution; limited proteolysis; thermostability assays of pathogenic mutants\",\n      \"pmids\": [\"29142233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the C-terminal PAF1-complex-interacting domain not solved\", \"No co-crystal with any binding partner\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of UBR5-mediated polyubiquitination at specific lysines (K243/K247/K257) as a Ser465-phosphorylation-dependent degradation mechanism established how CDC73 protein levels are post-translationally controlled.\",\n      \"evidence\": \"Ubiquitination assays with site-directed mutagenesis; co-immunoprecipitation; in vivo xenograft in triple-negative breast cancer\",\n      \"pmids\": [\"35551175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase responsible for Ser465 phosphorylation not identified\", \"Whether UBR5-mediated degradation is context-dependent across tissues not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Direct cross-linking of Cdc73 to the Spt6 tSH2 domain and to Rpb1 in vivo, combined with rapid Spt6 depletion causing genome-wide loss of Paf1C from chromatin, established Spt6 as a critical bridge anchoring the PAF1 complex to elongating Pol II.\",\n      \"evidence\": \"Site-specific protein cross-linking in yeast; in vitro binding assay; auxin-inducible degron depletion with ChIP-seq\",\n      \"pmids\": [\"36928138\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the Spt6–Cdc73 interaction is conserved in metazoans not tested\", \"No structure of the Spt6–Cdc73–Pol II ternary complex\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of specific tyrosine residues phosphorylated on CDC73 that govern the repressor/activator switch, the structural basis for competitive β-catenin/Gli/NICD binding, and the full-length structure of CDC73 in complex with PAF1 complex subunits.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Phosphorylated tyrosine residues not mapped\", \"No full-length CDC73 structure or PAF1 complex co-structure\", \"Genome-wide target specificity of repression vs. activation functions not delineated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 7, 8, 10, 15, 16]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 6, 9]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 4, 5, 11, 24]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [12, 17]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 7, 8, 24]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [8, 9, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 10, 15, 16]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [6, 14]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 17]}\n    ],\n    \"complexes\": [\n      \"PAF1 complex\",\n      \"CPSF/CstF 3' processing complex\"\n    ],\n    \"partners\": [\n      \"PAF1\",\n      \"LEO1\",\n      \"CTR9\",\n      \"RNF20\",\n      \"RNF40\",\n      \"SUV39H1\",\n      \"CTNNB1\",\n      \"SPT6\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}